

# Jennifer Gill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5072691/publications.pdf>

Version: 2024-02-01

21  
papers

534  
citations

1162889

8  
h-index

752573

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

959  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. <i>JAMA Network Open</i> , 2020, 3, e200423.	2.8	148
2	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. <i>European Journal of Cancer</i> , 2019, 106, 196-211.	1.3	127
3	A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. <i>ELife</i> , 2019, 8, .	2.8	71
4	Direct-to-Consumer Genetic Testing. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2377.	3.8	52
5	Improving observational studies in the era of big data. <i>Lancet</i> , The, 2018, 392, 716-717.	6.3	29
6	A reality check of the accelerated approval of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 656-658.	12.5	29
7	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 46-54.	1.7	16
8	Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. <i>JAMA Network Open</i> , 2019, 2, e1916091.	2.8	11
9	Pembrolizumab for Non-“Muscle-Invasive Bladder Cancer” A Costly Therapy in Search of Evidence. <i>JAMA Oncology</i> , 2021, 7, 501.	3.4	10
10	Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. <i>JAMA Internal Medicine</i> , 2020, 180, 797.	2.6	8
11	The response rate of alternative treatments for drugs approved on the basis of response rate. <i>International Journal of Cancer</i> , 2021, 148, 713-722.	2.3	8
12	Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither?. <i>American Journal of Medicine</i> , 2019, 132, 1260-1261.	0.6	5
13	The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. <i>BMC Cancer</i> , 2021, 21, 889.	1.1	5
14	Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. <i>American Journal of Medicine</i> , 2019, 132, 718-721.	0.6	3
15	A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2020, 6, 736-738.	3.8	3
16	Multi-cancer screening tests: communicating about risks should be prioritized.. <i>American Journal of Medicine</i> , 2021, , .	0.6	3
17	Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. <i>Cmaj</i> , 2019, 191, E272-E273.	0.9	2
18	Registration studies - when should patients be deemed ineligible for aggressive therapy?. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 333-334.	12.5	2

#	ARTICLE	IF	CITATIONS
19	A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 19-22.	1.0	1
20	N of 1 Data Sharing: The Impact of Data Sharing within the Hematology/Oncology Drug Products Division of the US FDA. Trends in Cancer, 2021, 7, 395-399.	3.8	1
21	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clinic Proceedings, 2021, 96, 2305-2308.	1.4	0